Cell Function
VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs
VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal
Novartis plans global filings after ianalumab hits primary endpoints in two Phase 3 Sjögren’s disease trials
Novartis; ianalumab; BAFF‑R; B-cell depletion; Sjögren’s disease; NEPTUNUS-1; NEPTUNUS-2; ESSDAI; Phase 3; regulatory filings; first targeted treatment; safety profile
NextCure Partners with Simcere for Novel ADC in $745M Deal
NextCure; Simcere; Antibody-Drug Conjugate; ADC; SIM0505; CDH6 Targeting
AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer
Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
Ataxia, Spinocerebellar, Stemchymal, Machado-Joseph Disease, Spinocerebellar, Ataxia, Mesenchymal Stem Cells
Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme
Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting
GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech
Abetalipoproteinemia, SmithKline Beecham, Bio, Grabody-B, Neurodegenerative Disorders, Blood – brain barrier anatomy, IGF1R gene
Sanofi adds new inflammatory target to growing Nurix tie-up
Nurix, sanofi, Target, STAT6 protein, human, cellular targeting, Collaboration, Inflammation, Autoimmune Diseases, TRANSCRIPTION FACTOR, DEL-AI
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
Sanofi Expands Immunology Pipeline with $600M Acquisition of Dren Bio’s Novel B-Cell Depleting Bispecific Antibody
Bispecific antibody, Myeloid cell engager, B-cell depletion, Autoimmune diseases, Immunology pipeline, Phagocytosis, CD20-directed therapy